Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger and SCAN domain-containing protein 26 (ZSCAN26) is a member of the ZSCAN family of transcription factors, characterized by a C2H2-type zinc finger domain that mediates sequence-specific DNA binding and a conserved SCAN domain that facilitates protein-protein interactions[2][3][4][6]. ZSCAN26 is predicted to function as a DNA-binding transcription factor, regulating the expression of genes by RNA polymerase II, and is primarily located in the cytosol and nucleoplasm[4][7]. While the ZSCAN family as a whole plays diverse roles in gene regulation related to processes such as cell proliferation, apoptosis, differentiation, and cancer biology, direct evidence linking ZSCAN26 specifically to individual diseases, therapeutic targeting, or drug interactions is currently lacking[1][2][3][4]. The SCAN domain enables dimerization or oligomerization with other SCAN-containing proteins, which may modulate its transcriptional activity and biological effects[1][2][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zinc finger and SCAN domain-containing protein 26 (ZSCAN26).